{
    "clinical_study": {
        "@rank": "112486", 
        "arm_group": {
            "arm_group_label": "Rotigotine", 
            "arm_group_type": "Experimental", 
            "description": "First application of Rotigotine patch for 24 hours on Day 1, followed by application of a new patch each day of the Treatment Period.\nSubjects on lower doses switch from Pramipexole or Ropinirole to equivalence doses of Rotigotine on Day 1 of the 28 days Treatment Period. On Day 8 (Visit 3) the dose will be evaluated and potentially adjusted up to a maximum dose of 8 mg / 24 hours.\nSubjects on higher doses switch from the equivalent dose to 8 mg / 24 hours Rotigotine of Pramipexole or Ropinirole to 8 mg / 24 hours Rotigotine on Day 1 and the remainder of the dose of Pramipexole or Ropinirole is to be switched on Day 8 of the 28 days Treatment Period. On Day 15 (Visit 4) the dose will be evaluated and potentially adjusted up to a maximum dose of 16 mg / 24 hours."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and feasibility of switching subjects with\n      advanced Parkinson's Disease (PD) from Pramipexole or Ropinirole to Rotigotine and to assess\n      the effects of Rotigotine on motor and non-motor symptoms of Parkinson's Disease in subjects\n      switched from previous treatment with either Pramipexole or Ropinirole."
        }, 
        "brief_title": "A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "First application of Rotigotine patch for 24 hours on Day 1, followed by application of a new patch each day of the Treatment Period.\nSubjects on lower doses switch from Pramipexole or Ropinirole to equivalence doses of Rotigotine on Day 1 of the 28 days Treatment Period. On Day 8 (Visit 3) the dose will be evaluated and potentially adjusted up to a maximum dose of 8 mg / 24 hours.\nSubjects on higher doses switch from the equivalent dose to 8 mg / 24 hours Rotigotine of Pramipexole or Ropinirole to 8 mg / 24 hours Rotigotine on Day 1 and the remainder of the dose of Pramipexole or Ropinirole is to be switched on Day 8 of the 28 days Treatment Period. On Day 15 (Visit 4) the dose will be evaluated and potentially adjusted up to a maximum dose of 16 mg / 24 hours.\nRotigotine: Rotigotine up to 16 mg / 24 hours, 4 weeks.", 
                        "title": "Rotigotine"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "87"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "8.5", 
                                            "@value": "59.5"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "0"
                                            }
                                        }, 
                                        "sub_title": "<=18 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "60"
                                            }
                                        }, 
                                        "sub_title": "Between 18 and 65 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "27"
                                            }
                                        }, 
                                        "sub_title": ">=65 years"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Age", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "47"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "40"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "6"
                                            }
                                        }, 
                                        "sub_title": "United States"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "9"
                                            }
                                        }, 
                                        "sub_title": "Taiwan"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "1"
                                            }
                                        }, 
                                        "sub_title": "Malaysia"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "2"
                                            }
                                        }, 
                                        "sub_title": "Singapore"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "69"
                                            }
                                        }, 
                                        "sub_title": "Korea, Republic of"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Region of Enrollment", 
                            "units": "participants"
                        }
                    ]
                }, 
                "population": "Baseline characteristics refer to the Safety Set. The Safety Set consists of all subjects who had at least one patch application."
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "The CGI Item 4 was used to assess side effects. It ranges from 0 to 4 as follows:\n0 = Side effects not assessable\n1 = No side effects\n2 = Side effects do not significantly interfere with subject\u2019s functioning\n3 = Side effects significantly interfere with the subject\u2019s functioning\n4 = Side effects outweigh therapeutic efficacy.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "First application of Rotigotine patch for 24 hours on Day 1, followed by application of a new patch each day of the Treatment Period.\nSubjects on lower doses switch from Pramipexole or Ropinirole to equivalence doses of Rotigotine on Day 1 of the 28 days Treatment Period. On Day 8 (Visit 3) the dose will be evaluated and potentially adjusted up to a maximum dose of 8 mg / 24 hours.\nSubjects on higher doses switch from the equivalent dose to 8 mg / 24 hours Rotigotine of Pramipexole or Ropinirole to 8 mg / 24 hours Rotigotine on Day 1 and the remainder of the dose of Pramipexole or Ropinirole is to be switched on Day 8 of the 28 days Treatment Period. On Day 15 (Visit 4) the dose will be evaluated and potentially adjusted up to a maximum dose of 16 mg / 24 hours.\nRotigotine: Rotigotine up to 16 mg / 24 hours, 4 weeks.", 
                                "title": "Rotigotine"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "87"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "58"
                                                    }
                                                }, 
                                                "sub_title": "CGI Item 4 score of 1"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "26"
                                                    }
                                                }, 
                                                "sub_title": "CGI Item 4 score of 2"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "3"
                                                    }
                                                }, 
                                                "sub_title": "CGI Item 4 score of 3"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "0"
                                                    }
                                                }, 
                                                "sub_title": "CGI Item 4 score of 4"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "3"
                                                    }
                                                }, 
                                                "sub_title": "CGI Item 4 score of 3 or 4"
                                            }
                                        ]
                                    }, 
                                    "description": "The CGI Item 4 was used to assess side effects. It ranges from 0 to 4 as follows:\n0 = Side effects not assessable\n1 = No side effects\n2 = Side effects do not significantly interfere with subject\u2019s functioning\n3 = Side effects significantly interfere with the subject\u2019s functioning\n4 = Side effects outweigh therapeutic efficacy.", 
                                    "param": "Number", 
                                    "title": "Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period or Early Withdrawal Visit", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "population": "All 87 subjects of the Safety Set are included in the analysis of this outcome measure. Last Observation Carried Forward (LOCF) was used as a method of imputation for missing observations.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 28 (Visit 5) of the 28 days Treatment Period or Early Withdrawal Visit", 
                        "title": "Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period or Early Withdrawal Visit", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "The PGIC is a 7-point categorical rating scale in which the subject rates the changes in functioning over time as follows:\n1 = Very much improved\n2 = Much improved\n3 = Minimally improved\n4 = No change\n5 = Minimally worse\n6 = Much worse\n7 = Very much worse.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "First application of Rotigotine patch for 24 hours on Day 1, followed by application of a new patch each day of the Treatment Period.\nSubjects on lower doses switch from Pramipexole or Ropinirole to equivalence doses of Rotigotine on Day 1 of the 28 days Treatment Period. On Day 8 (Visit 3) the dose will be evaluated and potentially adjusted up to a maximum dose of 8 mg / 24 hours.\nSubjects on higher doses switch from the equivalent dose to 8 mg / 24 hours Rotigotine of Pramipexole or Ropinirole to 8 mg / 24 hours Rotigotine on Day 1 and the remainder of the dose of Pramipexole or Ropinirole is to be switched on Day 8 of the 28 days Treatment Period. On Day 15 (Visit 4) the dose will be evaluated and potentially adjusted up to a maximum dose of 16 mg / 24 hours.\nRotigotine: Rotigotine up to 16 mg / 24 hours, 4 weeks.", 
                                "title": "Rotigotine"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "84"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "5"
                                                    }
                                                }, 
                                                "sub_title": "PGIC category 1"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "17"
                                                    }
                                                }, 
                                                "sub_title": "PGIC category 2"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "30"
                                                    }
                                                }, 
                                                "sub_title": "PGIC category 3"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "18"
                                                    }
                                                }, 
                                                "sub_title": "PGIC category 4"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "10"
                                                    }
                                                }, 
                                                "sub_title": "PGIC category 5"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "3"
                                                    }
                                                }, 
                                                "sub_title": "PGIC category 6"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "1"
                                                    }
                                                }, 
                                                "sub_title": "PGIC category 7"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "14"
                                                    }
                                                }, 
                                                "sub_title": "PGIC category \u2265 5"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "4"
                                                    }
                                                }, 
                                                "sub_title": "PGIC category \u2265 6"
                                            }
                                        ]
                                    }, 
                                    "description": "The PGIC is a 7-point categorical rating scale in which the subject rates the changes in functioning over time as follows:\n1 = Very much improved\n2 = Much improved\n3 = Minimally improved\n4 = No change\n5 = Minimally worse\n6 = Much worse\n7 = Very much worse.", 
                                    "param": "Number", 
                                    "title": "Patients Global Impressions of Change (PGIC) at the End of the Treatment Period or Early Withdrawal Visit", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "population": "Full Analysis Set (FAS) with Last Observation Carried Forward (LOCF) as a method of imputation for missing observations. FAS includes all subjects with at least 1 patch application during Treatment Period, and with an evaluable UPDRS Part III total score at Baseline and at least 1 valid value after Baseline to Day 35.", 
                        "safety_issue": "No", 
                        "time_frame": "Day 28 (Visit 5) of the 28 days Treatment Period or Early Withdrawal Visit", 
                        "title": "Patients Global Impressions of Change (PGIC) at the End of the Treatment Period or Early Withdrawal Visit", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "First application of Rotigotine patch for 24 hours on Day 1, followed by application of a new patch each day of the Treatment Period.\nSubjects on lower doses switch from Pramipexole or Ropinirole to equivalence doses of Rotigotine on Day 1 of the 28 days Treatment Period. On Day 8 (Visit 3) the dose will be evaluated and potentially adjusted up to a maximum dose of 8 mg / 24 hours.\nSubjects on higher doses switch from the equivalent dose to 8 mg / 24 hours Rotigotine of Pramipexole or Ropinirole to 8 mg / 24 hours Rotigotine on Day 1 and the remainder of the dose of Pramipexole or Ropinirole is to be switched on Day 8 of the 28 days Treatment Period. On Day 15 (Visit 4) the dose will be evaluated and potentially adjusted up to a maximum dose of 16 mg / 24 hours.\nRotigotine: Rotigotine up to 16 mg / 24 hours, 4 weeks.", 
                        "title": "Rotigotine"
                    }
                }, 
                "period_list": {
                    "period": {
                        "drop_withdraw_reason_list": {
                            "drop_withdraw_reason": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "3", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Noncompliant"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "3", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Withdrawal by Subject"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "2", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Adverse Event"
                                }
                            ]
                        }, 
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "87", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "79", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "8", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "recruitment_details": "This multicenter study started to enroll subjects in September 2012 in order to enroll 87 subjects in 5 countries.\nParticipant Flow refers to the Safety Set (SS). SS consists of all subjects who were enrolled and had at least 1 patch applied during the Treatment Period."
            }, 
            "point_of_contact": {
                "name_or_title": "UCB Clinical Trial Call Center", 
                "organization": "UCB", 
                "phone": "+1 877 822 9493"
            }, 
            "reported_events": {
                "desc": "Adverse Events refer to the Saftey Set. Safety Set consists of all subjects who were enrolled and had at least 1 patch applied during the Treatment Period.", 
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "First application of Rotigotine patch for 24 hours on Day 1, followed by application of a new patch each day of the Treatment Period.\nSubjects on lower doses switch from Pramipexole or Ropinirole to equivalence doses of Rotigotine on Day 1 of the 28 days Treatment Period. On Day 8 (Visit 3) the dose will be evaluated and potentially adjusted up to a maximum dose of 8 mg / 24 hours.\nSubjects on higher doses switch from the equivalent dose to 8 mg / 24 hours Rotigotine of Pramipexole or Ropinirole to 8 mg / 24 hours Rotigotine on Day 1 and the remainder of the dose of Pramipexole or Ropinirole is to be switched on Day 8 of the 28 days Treatment Period. On Day 15 (Visit 4) the dose will be evaluated and potentially adjusted up to a maximum dose of 16 mg / 24 hours.\nRotigotine: Rotigotine up to 16 mg / 24 hours, 4 weeks.", 
                        "title": "Rotigotine"
                    }
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "30", 
                                            "@subjects_at_risk": "87"
                                        }, 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@events": "9", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "9", 
                                                "@subjects_at_risk": "87"
                                            }, 
                                            "sub_title": "Application site pruritus"
                                        }, 
                                        {
                                            "counts": {
                                                "@events": "6", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "6", 
                                                "@subjects_at_risk": "87"
                                            }, 
                                            "sub_title": "Application site erythema"
                                        }
                                    ]
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@events": "6", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "6", 
                                                "@subjects_at_risk": "87"
                                            }, 
                                            "sub_title": "Dizziness"
                                        }, 
                                        {
                                            "counts": {
                                                "@events": "6", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "6", 
                                                "@subjects_at_risk": "87"
                                            }, 
                                            "sub_title": "Dyskinesia"
                                        }
                                    ]
                                }, 
                                "title": "Nervous system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@events": "5", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "5", 
                                                "@subjects_at_risk": "87"
                                            }, 
                                            "sub_title": "Erythema"
                                        }, 
                                        {
                                            "counts": {
                                                "@events": "5", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "5", 
                                                "@subjects_at_risk": "87"
                                            }, 
                                            "sub_title": "Pruritus"
                                        }
                                    ]
                                }, 
                                "title": "Skin and subcutaneous tissue disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA 16.0", 
                    "frequency_threshold": "5"
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "87"
                                        }, 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@events": "1", 
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "87"
                                        }, 
                                        "sub_title": "Hepatocellular carcinoma"
                                    }
                                }, 
                                "title": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA 16.0"
                }, 
                "time_frame": "Adverse Events (AEs) were collected over the whole study duration from the Screening Period (Day -28 to Day -1) to the Safety Follow-up Visit (up to Day 54)."
            }
        }, 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Advanced Idiopathic Parkinson's Disease", 
        "condition_browse": {
            "mesh_term": "Parkinson Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has idiopathic Parkinson's Disease of more than 3 years duration, as defined\n             by the cardinal sign, bradykinesia, plus the presence of at least 1 of the following:\n             resting tremor, rigidity, impairment of postural reflexes and is without any other\n             known or suspected cause of Parkinsonism\n\n          -  Subject has motor fluctuations\n\n          -  Subject is not satisfactorily controlled following the investigator\u00b4s assessment on a\n             total daily dose of Pramipexole or Ropinirole\n\n          -  Subject has sleep disturbance or early morning motor impairment\n\n          -  Subject has experienced nocturia for at least 3 nights within 7 days prior to the\n             Baseline Visit\n\n          -  Subject is taking L-dopa in combination with Benserazide or Carbidopa and has been on\n             a stable dose of L-dopa for at least 28 days prior to the Baseline Visit\n\n        Exclusion Criteria:\n\n          -  Subject has had therapy with Tolcapone or Budipine\n\n          -  Subject is receiving therapy with one of the following drugs either concurrently or\n             within 28 days prior to Baseline (Visit 2): alpha-methyl dopa, metoclopramide,\n             reserpine, neuroleptics, monoamine oxidase A (MAO-A) inhibitors, methylphenidate, or\n             amphetamine\n\n          -  Subject has a history of symptomatic (not asymptomatic) orthostatic hypotension in\n             the 6 months prior to Baseline (Visit 2)\n\n          -  Subject has a history of significant skin hypersensitivity to adhesive or other\n             transdermal preparations, or recent unsolved contact dermatitis\n\n          -  Subject has a history of seizures or stroke within 1 year, or a history of myocardial\n             infarction within the last 6 months prior to enrollment\n\n          -  Subject is pregnant or nursing, or is of childbearing potential but (i) not\n             surgically sterile or (ii) not using adequate birth control methods (including at\n             least 1 barrier method) or (iii) not sexually abstinent or (iv) not at least 2 years\n             postmenopausal\n\n          -  Subject has a previous diagnosis of narcolepsy, sleep apnea syndrome, restless legs\n             syndrome, or periodic limb movement disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "87", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 18, 2012", 
        "firstreceived_results_date": "February 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01711866", 
            "org_study_id": "PD0009"
        }, 
        "intervention": {
            "arm_group_label": "Rotigotine", 
            "description": "Rotigotine up to 16 mg / 24 hours, 4 weeks.", 
            "intervention_name": "Rotigotine", 
            "intervention_type": "Drug", 
            "other_name": "Neupro"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "N 0437", 
                "Pramipexol", 
                "Ropinirole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Rotigotine", 
            "Neupro", 
            "Switch", 
            "Dopamine agonists"
        ], 
        "lastchanged_date": "February 25, 2014", 
        "link": [
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"
            }, 
            {
                "description": "Product Information", 
                "url": "http://www.neupro.com/pdf/Neupro-PI.pdf"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anniston", 
                        "country": "United States", 
                        "state": "Alabama"
                    }, 
                    "name": "505"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlantis", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "506"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami Springs", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "508"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia"
                    }, 
                    "name": "502"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dayton", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "501"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma"
                    }, 
                    "name": "509"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "101"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Busan", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "102"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "108"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "109"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gyeonggi-Do", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "105"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "103"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "104"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "107"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "106"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sarawak", 
                        "country": "Malaysia"
                    }, 
                    "name": "202"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore"
                    }, 
                    "name": "401"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Singapore", 
                        "country": "Singapore"
                    }, 
                    "name": "403"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Linkou", 
                        "country": "Taiwan"
                    }, 
                    "name": "301"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan"
                    }, 
                    "name": "304"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan"
                    }, 
                    "name": "305"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Korea, Republic of", 
                "Malaysia", 
                "Singapore", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label, Multicenter, Multinational Study to Assess the Feasibility of Switching Therapy From Pramipexole or Ropinirole to the Rotigotine Transdermal System and Its Effect on Motor and Non-Motor Symptoms in Subjects With Advanced Idiopathic Parkinson's Disease Phase 4", 
        "overall_official": {
            "affiliation": "+1 877 822 9493 (UCB)", 
            "last_name": "UCB Clinical Trial Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "South Korea: Korea Food and Drug Administration (KFDA)", 
                "Taiwan : Food and Drug Administration", 
                "Malaysia: Ministry of Health", 
                "Singapore: Health Sciences Authority"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The CGI Item 4 was used to assess side effects. It ranges from 0 to 4 as follows:\n0 = Side effects not assessable\n1 = No side effects\n2 = Side effects do not significantly interfere with subject's functioning\n3 = Side effects significantly interfere with the subject's functioning\n4 = Side effects outweigh therapeutic efficacy.", 
            "measure": "Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period or Early Withdrawal Visit", 
            "safety_issue": "No", 
            "time_frame": "Day 28 (Visit 5) of the 28 days Treatment Period or Early Withdrawal Visit"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01711866"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The PGIC is a 7-point categorical rating scale in which the subject rates the changes in functioning over time as follows:\n1 = Very much improved\n2 = Much improved\n3 = Minimally improved\n4 = No change\n5 = Minimally worse\n6 = Much worse\n7 = Very much worse.", 
            "measure": "Patients Global Impressions of Change (PGIC) at the End of the Treatment Period or Early Withdrawal Visit", 
            "safety_issue": "No", 
            "time_frame": "Day 28 (Visit 5) of the 28 days Treatment Period or Early Withdrawal Visit"
        }, 
        "source": "UCB, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "UCB BIOSCIENCES GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}